Last mentioned: 6d ago
Across the most recent 3 stories covering Democratic Republic of Congo — 100% negative sentiment, averaging 8/10 impact.
This entity profile aggregates every story where the entity meets our minimum relevance threshold before it is linked here — a story naming this entity only in passing, as competitive context for an unrelated subject, does not qualify. That threshold exists because earlier testing surfaced entity pages cluttered with tangential mentions: a story about two unrelated companies merging could otherwise populate a third company's page simply because it was named once for comparison, with no real event of its own. The timeline below reflects genuine milestones and developments specific to this entity, cross-referenced against the same source-verification standard applied to every story on this site. Sentiment measures the directional read of each development for this entity specifically, not the overall tone of the reporting, and impact weights how consequential a development is rather than how widely it was syndicated across outlets.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
The Bundibugyo ebolavirus outbreak in Congo has no approved vaccine or treatment, creating a pressing unmet medical need. With 894 cases and over 200 deaths, the crisis could accelerate biopharma R&D for neglected filovirus strains.
75 healthcare workers infected with the Ebola Bundibugyo strain in DRC expose critical gaps in vaccine coverage and trial infrastructure, pressuring biopharma to accelerate strain-specific countermeasures.
Source: yahoo.com · medscape.com
At least 30 deaths with Ebola symptoms in a crowded DRC camp highlight untreated spread and demand for rapid point-of-care diagnostics and expanded vaccine access. With 5 million displaced at risk, biopharma firms face calls to accelerate countermeasure deployment.
Source: tribune.com.pk · examiner.com.au
This page surfaces every story mentioning Democratic Republic of Congo across our biotech coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.
Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running biotech beat. Cross-entity comparisons live on our compare view.
Entities only appear on this page once the classifier scores them at a minimum 35 percent relevance to the story, filtering out passing mentions. According to that methodology, reviewed July 2026, this follows multi-source corroboration standards recommended by journalism research bodies such as the Reuters Institute for the Study of Journalism.
| What you see | What it tells you |
|---|---|
| Story count | Number of distinct stories where Democratic Republic of Congo was a primary or referenced actor. |
| Recency clustering | Whether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc). |
| Sentiment distribution | Aggregate sentiment of the stories mentioning this entity, weighted by impact score. |
| Cross-niche links | When the same entity surfaces in our sibling networks, we link to those views to enrich context. |